Home  |  Corporate Info  |  R & D  |  Products  |  Investor Relations  |  Careers at Hemispherx  


 

Hemispherx Biopharma Investor Relations

Welcome to Hemispherx Biopharma Investor Relations! In this section you can view the most recent Hemispherx press releases, SEC filings, including the 10K & 10Q, as well as obtain the contact information for the Company's Investor Relations contact, transfer agent and auditor. You may also request to receive news releases by e-mail.

Recent News:

 

2/3/2016 Hemispherx Biopharma Introduces a Voluntary Stock Purchase Plan to Create Shareholder Value
… Senior Management, Entire Board of Directors, and 100% of All Employees Participate


1/20/2016 Hemispherx Biopharma Europe N.V./S.A. : Orphan Medicine Designation and European Medicines Agency Public Opinion Summary Published by EMA Regarding Alferon N Injection® as a Treatment of Middle East Respiratory Syndrome (MERS)

11/17/2015 Hemispherx Biopharma Announces Financial Results for the Nine Months Ended September 30, 2015
… Long Term Exclusivity in Promising Novel Nucleic Acid Treatments Supported by Recent Issuance of a Broad Patent in European Union


10/19/2015 Hemispherx Biopharma Europe N.V./S.A. Receives Positive Opinion on Application for Orphan Designation by the European Medicines Agency for Alferon N Injection to Treat Patients with Middle East Respiratory Syndrome (MERS)
…..Hemispherx’ Next Step in the Fight to Treat Patients with MERS


9/30/2015 New Arrowhead Analyst Issues Updated Diligence and Valuation Report on Hemispherx Biopharma

More Releases...

Click Here for a complete archive

Transfer Agent

Continental Stock Transfer & Trust Company
Shareowner Services
2 Broadway
New York, New York 10004 
Tel: 212-509-4000
Fax: 212-509-5150

Independent Public Accountants

McGladrey & Pullen, LLP

 

Investor Relations:

Charles Jones
CJones & Associates Public Relations
888-557-6480
cjones@cjonespr.com